-

Precision BioSciences to Attend and Present at Upcoming September Investor Conferences

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that members of management will participate in the following investor conferences in the month of September:

H.C. Wainwright Annual Global Investment Conference 2023
Date: September 11, 2023
Time: Available on-demand at 7:00 am ET

Jefferies Gene Editing/Gene Therapy Summit
Date: September 27, 2023
Time: 8:30 am ET

Live webcasts will be accessible on Precision’s website in the Investors section under Events & Presentations at https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Contacts

Mei Burris
Director, Investor Relations and Finance
Mei.Burris@precisionbiosciences.com

Industry:

Precision BioSciences, Inc.

NASDAQ:DTIL
Details
Headquarters: Durham, United States
CEO: Michael Amoroso
Employees: 250
Organization: PUB
Release Versions
English

Contacts

Mei Burris
Director, Investor Relations and Finance
Mei.Burris@precisionbiosciences.com

More News From Precision BioSciences, Inc.

Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stock...

Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced new and updated Phase 1 clinical data from the ongoing ELIMINATE-B study of PBGENE-HBV to be presented in a late-breaking oral presentation on Sunday, November 8 at 2:15pm MST, at the American Association for the Study of Liver Diseases (AASLD) The L...

Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from the first patient treated with PBGENE-DMD in the Phase 1/2 FUNCTION-DMD clinical trial for Duchenne muscular dystrophy (DMD). No serious adverse eve...
Back to Newsroom